What’s the current market cap for Teva Pharmaceutical stock?

Teva Pharmaceutical (TEVA) has a market cap of $41B as of June 01, 2026.

What is the P/E ratio for Teva Pharmaceutical stock?

The price to earnings (P/E) ratio for Teva Pharmaceutical (TEVA) stock is 26.38 as of June 01, 2026.

Does Teva Pharmaceutical stock pay dividends?

No, Teva Pharmaceutical (TEVA) stock does not pay dividends to its shareholders as of June 01, 2026.

When is the next Teva Pharmaceutical dividend payment date?

Teva Pharmaceutical (TEVA) stock does not pay dividends to its shareholders.

What is the beta indicator for Teva Pharmaceutical?

Teva Pharmaceutical (TEVA) has a beta rating of 0.86. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy Teva Pharmaceutical stock | $TEVA Share Price

About Teva Pharmaceutical

Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.

Ticker

$TEVA

Sector

Health

Primary listing

NYSE

Employees

32,008

Headquarters

Tel Aviv-Yafo, Israel

Website

www.tevapharm.com

TEVA Metrics

BasicAdvanced

$41bn

26.38

$1.34

0.86

-

What the Analysts think about TEVA

Analyst ratings (Buy, Hold, Sell) for Teva Pharmaceutical stock.

Bulls say / Bears say

Momentum in Teva’s branded portfolio boosted Q1 2026 results, with Austedo sales jumping 41% year-on-year to $578 million and the three key branded drugs generating $3.1 billion in 2025—with expectations to reach $3.6 billion in 2026—helping Teva beat profit estimates (Reuters).

Teva posted strong Q4 2025 results, with adjusted EPS of $0.96 versus $0.71 the previous year and revenue up 11% to $4.71 billion, supported by a $500 million milestone payment from Sanofi, highlighting revenue diversity beyond generics (Reuters).

In Q1 2026, Teva announced the acquisition of Emalex Biosciences for $700 million upfront plus up to $200 million in milestones, gaining access to ecopipam and strengthening its CNS pipeline to support long-term growth goals (Reuters).

Global generics revenues fell 13% in Q1 2026, mainly due to the expected decline in generic Revlimid market share, highlighting growing pressure on Teva’s core generics business (Reuters via Investing.com).

Teva’s 2026 guidance was lowered, projecting group revenue of $16.4–16.8 billion and adjusted EPS of $2.57–2.77, down from $17.3 billion in revenue and $2.93 EPS for 2025, reflecting an expected loss exceeding $1 billion in Revlimid revenue from increased competition (Reuters).

CEO Richard Francis warned that it is “hard to understand and predict” whether Austedo sales will decline ahead of price negotiations under the U.S. Inflation Reduction Act in 2027, potentially putting pressure on Teva’s margins and growth outlook (Reuters).

Data summarised monthly by Lightyear AI. Last updated on 22 May 2026.

TEVA Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

TEVA Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

TEVA News

AllArticlesVideos

Teva Pharmaceuticals CEO on acquiring Emalex Biosciences, drug portfolio

CNBC Television·1 month ago

Teva Signals Confidence With $700 Million Pipeline Push, Buyback Plan

Benzinga·1 month ago

Teva Pharmaceutical beats first-quarter profit estimates on branded drugs demand

Reuters·1 month ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.